title: [Intraoperative electron irradiation (IORT) of urologic tumors. Initial results of a pilot study of local recurrences of renal cell cancers].
abstract: The efficacy of radiotherapy of renal cell carcinomas is limited by its side effects. To avoid gastrointestinal problems the dose must not exceed 45 Gy, but with corresponding protocols no effect has been seen in curative and adjuvant trials. A new three-step protocol combining surgery with intraoperative radiotherapy focussed on the tumor bed fading out the intestine (IORT) and external boost radiotherapy (40 Gy) was used in six patients with local recurrences after tumor nephrectomy. No increase in morbidity was induced by IORT. One year after radiotherapy no recurrences have been seen in the radiation field. We recommend this protocol for patients with solitary local recurrences and for tumors of clinical stage T3 and T4.
authors.affiliation: Abteilung Urologie, Chirurgische Universitätsklinik Heidelberg.
authors.forename: M
authors.initials: M
authors.lastname: Beer
authors.forename: M J
authors.initials: MJ
authors.lastname: Eble
authors.forename: M
authors.initials: M
authors.lastname: Wannenmacher
authors.forename: G
authors.initials: G
authors.lastname: Staehler
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D004583:Electrons / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D015182:Lymphatic Irradiation; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D009367:Neoplasm Staging; D009392:Nephrectomy; D009873:Operating Rooms; D010865:Pilot Projects; D011879:Radiotherapy Dosage; D013523:Surgical Equipment
vernacular_title: Die intraoperative Elektronenbestrahlung (IORT) bei urologischen Tumoren. Erste Ergebnisse einer Pilotstudie an Lokalrezidiven von Nierenzellkarzinomen.